HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

Angelo Di Leo, Christine Desmedt, John M S Bartlett, Fanny Piette, Bent Ejlertsen, Kathleen I Pritchard, Denis Larsimont, Christopher Poole, Jorma Isola, Helena Earl, Henning Mouridsen, Frances P O'Malley, Fatima Cardoso, Minna Tanner, Alison Munro, Chris J Twelves, Christos Sotiriou, Lois Shepherd, David Cameron, Martine J PiccartMarc Buyse, HER2/TOP2A Meta-analysis Study Group

    164 Citationer (Scopus)

    Abstract

    Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer.
    OriginalsprogEngelsk
    TidsskriftLancet Oncology
    Vol/bind12
    Udgave nummer12
    Sider (fra-til)1134-42
    Antal sider9
    ISSN1470-2045
    DOI
    StatusUdgivet - nov. 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data'. Sammen danner de et unikt fingeraftryk.

    Citationsformater